Quickgene

Updates

New analytical methods, application notes, impurity standards and other changes to our services, newest first.

November 2026

  1. Application noteTechnical article — SEC for aggregates and fragments: system suitability, ChP/USP/EP criteria and integration rules
  2. Application noteTechnical article — residual HCP and Protein A immunoassays: antibody coverage, bridging and the hook effect
  3. Impurity standardsImpurity library: five cagrilintide standards added (free acid, reduced form, disulfide dimers, [Asp21])
  4. Application noteTechnical article — amino acid analysis: hydrolysis recovery, molar-ratio reporting and net peptide content
  5. Application noteRegulatory: key points of the EMA synthetic peptide guideline (effective 1 June 2026)
  6. Application noteRegulatory: synthetic peptide requirements compared — China CDE, US FDA and EU EMA
  7. Application noteTechnical article — CD secondary structure: reference sets, concentration normalization and HT-voltage cut-offs
  8. New productNew product: CHO-GLP-1 luciferase reporter cell line (T82011) for GLP-1R potency testing
  9. Application noteTechnical article — icIEF charge heterogeneity: pI calibration, focusing completeness and peak-area limits
  10. New methodFour new method pages: SV-AUC, circular dichroism, icIEF and cell-based bioassay
  11. WebsiteThe website is now available in Spanish and Portuguese

October 2026

  1. Impurity standardsImpurity library: 342 reference standards for semaglutide, tirzepatide and retatrutide
  2. Molecule guidesMolecule guides for semaglutide, tirzepatide, retatrutide and cagrilintide
  3. New methodCell-based bioactivity and relative potency assays added to our services

September 2026

  1. Application noteApplication note — AUC vs SEC: is the 1% on your report really 1% in your sample?